AstraZeneca's Cediranib Filing Withdrawal: CHMP Had Two Major Issues
Executive Summary
European filing for ovarian cancer candidate cediranib was undone by differences in opinion between AstraZeneca and EMA's CHMP advisory committee in two key areas – the clinical benefit, and compliance with GCP.
You may also be interested in...
“Excellence In Execution” Is Key To AstraZeneca’s Bid To Be An Oncology Leader
Though AstraZeneca is in several ways playing catch up in the oncology space, a strategy built around speed, differentiation and carving out areas of leadership has the firm poised for transformation. Execs are particularly confident the company will become a dominant force as combinations become a larger part of cancer care, pulling from its immunotherapeutic and small molecule pipelines.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.